Cognitive Impairment Associated with Schizophrenia: a Review of the Humanistic Burden

被引:58
作者
Kitchen, Helen [1 ]
Rofail, Diana
Heron, Louise
Sacco, Pat [2 ]
机构
[1] Adelphi Mill, Adelphi Values, Bollington SK10 5JB, Cheshire, England
[2] Novartis Pharmaceut, E Hanover, NJ USA
关键词
burden; cognitive impairment associated with schizophrenia; conceptual model; cost; humanistic; patient reported outcome; schizophrenia; QUALITY-OF-LIFE; ANTIPSYCHOTIC MEDICATIONS; 2ND-GENERATION ANTIPSYCHOTICS; CONVENTIONAL ANTIPSYCHOTICS; 1ST-EPISODE SCHIZOPHRENIA; ATYPICAL ANTIPSYCHOTICS; EXECUTIVE FUNCTION; NEGATIVE SYMPTOMS; ECONOMIC BURDEN; UNITED-STATES;
D O I
10.1007/s12325-012-0001-4
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Introduction: Nearly every individual with schizophrenia is affected by cognitive decline. The aim of this literature review was to: (a) describe the humanistic burden of cognitive impairment associated with schizophrenia (CIAS); (b) develop a conceptual model that depicts the signs and symptoms of CIAS along with key concepts important to patients; and (c) consider the adequacy of potential patient-reported outcome (PRO) instruments for assessing future treatments. Methods: The following electronic databases were searched for articles published between January 1999 and November 2009 related to CIAS and PROs, or cost of illness: Medline; Embase; PsycINFO; the Health Economic Evaluation Database; and the National Health Service Economic Evaluation Database and Health Technology Assessment databases at the Centre for Reviews and Dissemination, University of York. Results: The literature search revealed 3950 abstracts, of which 101 articles were reviewed in detail. Cognitive functions affected include memory, attention/concentration, problem solving, learning, executive function, processing speed, and social cognition. Cognitive impairment impacts the ability of individuals to carry out activities of daily living, work productively, function socially, and adhere to treatment. These effects have economic ramifications through increased direct and indirect costs associated with the treatment of schizophrenia. The literature revealed 39 PRO instruments that have been used to assess functioning. However, no single instrument captures all key concepts of importance to patients with schizophrenia. Conclusion: The significant burden from CIAS for patients and society has implications for designing future treatments and health strategies to improve functional outcomes.
引用
收藏
页码:148 / 162
页数:15
相关论文
共 81 条
[1]  
[Anonymous], 2009, CTR REV DISS SYST RE
[2]  
[Anonymous], MENT HLTH SUBST AB F
[3]  
[Anonymous], 2011, DIAGN STAT MAN MENT, V5th
[4]   Does negative symptom change relate to neurocognitive change in schizophrenia? Implications for targeted treatments [J].
Bell, MD ;
Mishara, AL .
SCHIZOPHRENIA RESEARCH, 2006, 81 (01) :17-27
[5]   A review of compliance, depot intramuscular antipsychotics and the new long-acting injectable atypical antipsychotic risperidone in schizophrenia [J].
Bhanji, NH ;
Chouinard, G ;
Margolese, HC .
EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2004, 14 (02) :87-92
[6]   Neuropsychology of first-episode schizophrenia: Initial characterization and clinical correlates [J].
Bilder, RM ;
Goldman, RS ;
Robinson, D ;
Reiter, G ;
Bell, L ;
Bates, JA ;
Pappadopulos, E ;
Willson, DF ;
Alvir, JMJ ;
Woerner, MG ;
Geisler, S ;
Kane, JM ;
Lieberman, JA .
AMERICAN JOURNAL OF PSYCHIATRY, 2000, 157 (04) :549-559
[7]   THE SOCIAL FUNCTIONING SCALE - THE DEVELOPMENT AND VALIDATION OF A NEW SCALE OF SOCIAL-ADJUSTMENT FOR USE IN FAMILY INTERVENTION PROGRAMS WITH SCHIZOPHRENIC-PATIENTS [J].
BIRCHWOOD, M ;
SMITH, J ;
COCHRANE, R ;
WETTON, S ;
COPESTAKE, S .
BRITISH JOURNAL OF PSYCHIATRY, 1990, 157 :853-859
[8]  
Bowie Christopher R, 2006, Neuropsychiatr Dis Treat, V2, P531, DOI 10.2147/nedt.2006.2.4.531
[9]   Medications and verbal memory impairment in schizophrenia:: the role of anticholinergic drugs [J].
Brébion, G ;
Bressan, RA ;
Amador, X ;
Malaspina, D ;
Gorman, JM .
PSYCHOLOGICAL MEDICINE, 2004, 34 (02) :369-374
[10]   A summary of the FDA-NIMH-MATRICS Workshop on Clinical Trial Design for Neurocognitive Drugs for Schizophrenia. [J].
Buchanan, RW ;
Davis, M ;
Goff, D ;
Green, MF ;
Keefe, RSE ;
Leon, AC ;
Nuechterlein, KH ;
Laughren, T ;
Levin, R ;
Stover, E ;
Fenton, W ;
Marder, SR .
SCHIZOPHRENIA BULLETIN, 2005, 31 (01) :5-19